Psilocybin has recently come under close observation due to the overwhelming evidence showing positive results in cases of depression, PTSD, stress, and other mental/emotional disharmonies. Much of this research was stunted due to the illegalization of this plant medicine in 1968. Psilocybin and psilocin became classified as Schedule 1 drugs (the same category heroin and cocaine are classified) and the quest for analysis stood still (well, in the legal sense).
Thanks to the dedication of grassroots organizations, striving to decriminalize plant medicine, and the scientists, psychologists and other professionals in the field recording proof of neurological improvement, legalization of this precious resource is slowly underway here in the United States.
Take a look at the research below and check back often as we update regularly.
Trip of a lifetime: Can a single dose of a hallucinogenic drug lead to lasting improvements in mental health? Researchers are studying the potential of these drugs to treat such diverse conditions as severe depression, opioid dependence, anorexia and more
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Psychedelics in the treatment of depression, anxiety, and obsessive-compulsive disorder
Treatment-Resistant Depression: Approaches to Treatment
Psilocybin as Treatment for Depression
The therapeutic potential of microdosing psychedelics in depression
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Psychedelics as an aid to addiction recovery
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
Efficacy of psychedelics in psychiatry, a systematic review of the literature